Use of nanoparticles for cerebral cancer

Tumori. 2008 Mar-Apr;94(2):271-7. doi: 10.1177/030089160809400220.

Abstract

Nanoparticles made of poly(butyl cyanoacrylate) (PBCA) or poly(lactic-co-glycolic acid) (PLGA) coated with polysorbate 80 or poloxamer 188 enable the transport of cytostatics such as doxorubicin across the blood-brain barrier (BBB). Following intravenous injection to rats bearing intracranially the very aggressive glioblastoma 101/8 these particles loaded with doxorubicin significantly increased the survival times and led to a complete tumor remission in 20-40% of the animals. Moreover, these particles considerably reduced the dose-limiting cardiotoxicity and also the testicular toxicity of this drug. The drug transport across the BBB by nanoparticles appears to be due to a receptor-mediated interaction with the brain capillary endothelial cells, which is facilitated by certain plasma apolipoproteins adsorbed by nanoparticles in the blood.

MeSH terms

  • Animals
  • Antibiotics, Antineoplastic / administration & dosage*
  • Antibiotics, Antineoplastic / adverse effects
  • Blood-Brain Barrier* / drug effects
  • Blood-Brain Barrier* / metabolism
  • Brain Neoplasms* / diagnosis
  • Brain Neoplasms* / therapy
  • Capillaries / drug effects
  • Capillaries / metabolism
  • Cerebrovascular Circulation / drug effects
  • Doxorubicin / administration & dosage*
  • Doxorubicin / adverse effects
  • Drug Carriers*
  • Enbucrilate
  • Endothelial Cells / drug effects
  • Endothelial Cells / metabolism
  • Excipients
  • Humans
  • Lactic Acid
  • Nanoparticles*
  • Poloxamer
  • Polyglycolic Acid
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Polysorbates
  • Rats
  • Surface-Active Agents
  • Survival Analysis

Substances

  • Antibiotics, Antineoplastic
  • Drug Carriers
  • Excipients
  • Polysorbates
  • Surface-Active Agents
  • Poloxamer
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Polyglycolic Acid
  • Lactic Acid
  • Doxorubicin
  • Enbucrilate